IDYA Quote, Financials, Valuation and Earnings

Cellectar Biosciences has a net margin of -- compared to IDEAYA Biosciences's net margin of --. IDEAYA Biosciences's return on equity of -- beat Cellectar Biosciences's return on equity of --.

IDEAYA Biosciences has a consensus price target of $55.79, signalling upside risk potential of 121.72%. On the other hand Cellectar Biosciences has an analysts' consensus of $5.67 which suggests that it could grow by 1735.06%. Given that Cellectar Biosciences has higher upside potential than IDEAYA Biosciences, analysts believe Cellectar Biosciences is more attractive than IDEAYA Biosciences.

IDEAYA Biosciences has a beta of 0.792, which suggesting that the stock is 20.804% less volatile than S&P 500. In comparison Cellectar Biosciences has a beta of 0.891, suggesting its less volatile than the S&P 500 by 10.942%.

IDEAYA Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectar Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEAYA Biosciences pays -- of its earnings as a dividend. Cellectar Biosciences pays out -- of its earnings as a dividend.

IDEAYA Biosciences quarterly revenues are --, which are smaller than Cellectar Biosciences quarterly revenues of --. IDEAYA Biosciences's net income of -$51.8M is lower than Cellectar Biosciences's net income of -$14.7M. Notably, IDEAYA Biosciences's price-to-earnings ratio is -- while Cellectar Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences is 81.93x versus 657.46x for Cellectar Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals has a net margin of -- compared to IDEAYA Biosciences's net margin of -104.98%. IDEAYA Biosciences's return on equity of -- beat Ionis Pharmaceuticals's return on equity of -93.21%.

IDEAYA Biosciences has a consensus price target of $55.79, signalling upside risk potential of 121.72%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $61.36 which suggests that it could grow by 70.87%. Given that IDEAYA Biosciences has higher upside potential than Ionis Pharmaceuticals, analysts believe IDEAYA Biosciences is more attractive than Ionis Pharmaceuticals.

IDEAYA Biosciences has a beta of 0.792, which suggesting that the stock is 20.804% less volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.349, suggesting its less volatile than the S&P 500 by 65.148%.

IDEAYA Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEAYA Biosciences pays -- of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend.

IDEAYA Biosciences quarterly revenues are --, which are smaller than Ionis Pharmaceuticals quarterly revenues of $133.8M. IDEAYA Biosciences's net income of -$51.8M is higher than Ionis Pharmaceuticals's net income of -$140.5M. Notably, IDEAYA Biosciences's price-to-earnings ratio is -- while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences is 81.93x versus 6.53x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -- compared to IDEAYA Biosciences's net margin of 25.23%. IDEAYA Biosciences's return on equity of -- beat Pfizer's return on equity of 4.63%.

IDEAYA Biosciences has a consensus price target of $55.79, signalling upside risk potential of 121.72%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 19.7%. Given that IDEAYA Biosciences has higher upside potential than Pfizer, analysts believe IDEAYA Biosciences is more attractive than Pfizer.

IDEAYA Biosciences has a beta of 0.792, which suggesting that the stock is 20.804% less volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

IDEAYA Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.31% to investors and pays a quarterly dividend of $0.42 per share. IDEAYA Biosciences pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

IDEAYA Biosciences quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $17.7B. IDEAYA Biosciences's net income of -$51.8M is lower than Pfizer's net income of $4.5B. Notably, IDEAYA Biosciences's price-to-earnings ratio is -- while Pfizer's PE ratio is 35.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences is 81.93x versus 2.55x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -- compared to IDEAYA Biosciences's net margin of 37.71%. IDEAYA Biosciences's return on equity of -- beat Vertex Pharmaceuticals's return on equity of -2.89%.

IDEAYA Biosciences has a consensus price target of $55.79, signalling upside risk potential of 121.72%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $493.61 which suggests that it could grow by 20.76%. Given that IDEAYA Biosciences has higher upside potential than Vertex Pharmaceuticals, analysts believe IDEAYA Biosciences is more attractive than Vertex Pharmaceuticals.

IDEAYA Biosciences has a beta of 0.792, which suggesting that the stock is 20.804% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.631%.

IDEAYA Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEAYA Biosciences pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

IDEAYA Biosciences quarterly revenues are --, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. IDEAYA Biosciences's net income of -$51.8M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, IDEAYA Biosciences's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 25.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences is 81.93x versus 10.01x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.